SCHEMBL4494085

SCHEMBL4494085

NC(=O)c1cccc(N(c2cccc(C(N)=O)c2)S(=O)(=O)c2cc(S(N)(=O)=O)cc3ccc(O)cc23)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.40
ERN1 O75460 1/20 0.38
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
PTGES O14684 1/20 0.36
CA2 P00918 4/20 0.34
ESR1 P03372 1/20 0.34
CRY1 Q16526 1/20 0.33
CRY2 Q49AN0 1/20 0.33
CCNA2 P20248 1/20 0.33
CDK2 P24941 1/20 0.33
LCK P06239 1/20 0.33
CA12 O43570 2/20 0.32
CA1 P00915 2/20 0.32
CA9 Q16790 2/20 0.32
STS P08842 2/20 0.32
CA14 Q9ULX7 1/20 0.32
GLO1 Q04760 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4494785 0.85 ESR1 (0.49) PTGESCA2ESR1CA12CA1
SCHEMBL4511797 0.84 PTGES (0.37) PTGESCA2ESR1CA12CA1
SCHEMBL4497044 0.84 PTGES (0.45) TP53MAPTPTGESCA2ESR1
SCHEMBL4497601 0.84 RORC (0.41) PTGESCA2ESR1CA12CA1
SCHEMBL4500848 0.84 PTGES (0.37) PTGESCA2ESR1CA12CA1
SCHEMBL4506803 0.79 PTGES (0.38) PTGESCA2ESR1CA12CA1
SCHEMBL4512914 0.78 PTGES (0.39) PTGESCA2ESR1CA12CA1
SCHEMBL4499043 0.77 CA2 (0.41) PTGESCA2ESR1CA12CA1
SCHEMBL4500899 0.77 PTGES (0.46) PTGESCA2ESR1CA12CA1
SCHEMBL4511441 0.77 PTGES (0.40) PTGESCA2ESR1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090234014-A1 Naphthalene-Disulfonamides Useful for the Treatment of Inflammation BIOLIPOX AB (SE) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090234014-A1 Naphthalene-Disulfonamides Useful for the Treatment of Inflammation AREG, PRSS12, CXCL8 PARP1 4186/4885ERN1 2343/4885TP53 772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.